Upstream Bio, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-09 meeting.
“Proposal 2 - Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of PwC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of Proposal 2 were as follows: For Against Abstain 47,951,313 143,251 6,203”
Shareholder Votes
Upstream Bio, Inc. shareholders approved Election of Class II Directors at the 2026-06-09 meeting.
“The Company’s stockholders approved the Class II director nominees recommended for election in Proposal 1 at the Annual Meeting. The results of Proposal 1 were as follows: Class II Director Nominee For Withheld Broker Non-Votes H. Edward Fleming, Jr., M.D. 40,715,035 3,367,258 4,018,474 Liam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A. 43,812,021 270,272 4,018,474”
Earnings Releases
Upstream Bio, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $40.6 million for the quarter ended March 31, 2026.
“Net loss was $40.6 million for the quarter ended March 31, 2026, compared to a net loss of $27.3 million for the same period in 2025.”
Earnings Releases
Upstream Bio, Inc. reported financial results for the quarter and year ended December 31, 2025.
“On March 26, 2026, Upstream Bio, Inc. (the “Company”) announced its financial results and business highlights for the quarter and year ended December 31, 2025.”
Material Agreements
Upstream Bio, Inc. entered into Sales Agreement with Leerink Partners LLC valued at up to $150,000,000 (effective 2026-03-26).
“On March 26, 2026, Upstream Bio, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC, as sales agent (the “Agent”), pursuant to which the Company from time to time may offer and sell shares (the “ATM Shares”) of its common stock”
Governance Changes
Upstream Bio, Inc.: Second amended and restated bylaws became effective, eliminating stockholder ability to act by written consent, establishing advance notice procedure for stockholder proposals, and conforming to amended certificate (effective 2024-10-10).
“In addition, as previously disclosed in the Registration Statement, the second amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Board and the Company’s stockholders, became effective as of the effectiveness of the Registration Statement on October 10, 2024. The Amended and Restated Bylaws amend and restate the Company’s bylaws in their entirety to, among other things: (i) eliminate the ability of the Company’s stockholders to take action by written consent in lieu of a meeting and call special meetings of stockholders; (ii) establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our Board; and (iii) conform to the amended provisions of the Amended and Restated Certificate.”
Governance Changes
Upstream Bio, Inc.: Third amended and restated certificate of incorporation filed to increase authorized common stock to 500 million shares, eliminate references to previous series of preferred stock, and authorize 10 million shares of undesignated preferred stock (effective 2024-10-15).
“As previously disclosed in the Registration Statement on Form S-1, as amended (File No. 333-282197) (the “Registration Statement”), of Upstream Bio, Inc. (the “Company”), and in connection with the completion of the initial public offering of the Company’s common stock (the “IPO”), on October 15, 2024, the Company filed its third amended and restated certificate of incorporation (the “Amended and Restated Certificate”) with the Secretary of State of the State of Delaware. The Company’s board of directors (the “Board”) and the Company’s stockholders previously approved the Amended and Restated Certificate to be filed in connection with, and to be effective immediately prior to, the completion of the IPO. The Amended and Restated Certificate amends and restates the Company’s existing second amended and restated certificate of incorporation, as amended, in its entirety to, among other things: (i) authorize 500,000,000 shares of common stock; (ii) eliminate all references to the previously”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.